TapeBeat.com, the news and research portal for the serious bio-tech investor in conjunction with the Farseers Group is proud to profile one of the most exciting up and coming biotech companies, MedaSorb Technologies (MSBT.OB), which is perfectly poised to realize exponential growth.
MedaSorb Technologies is a medical device company that operates exclusively through its wholly owned subsidiary, CytoSorbents Inc. Their flagship medical device, the “CytoSorb™”, is a patented blood purification device that uses state of the art resin technology to remove toxins from the blood, allowing the recirculation of clean blood back into the body. Globally, about 20 million people a year develop sepsis and 1 out of every 3 dies from it. Severe Sepsis may occur as a result of a bacterial or viral infectious trigger or may be caused by certain virulent strains of influenza such as avian (H5N1) and swine (H1N1) flu.
Earlier this year the number of trial sites for The CytoSorb(TM) treatment was increased in keeping with the company’s goal to complete trial enrollment in 2009 then obtain CE Mark approval and initial commercial sales in Europe next year. Considering that the company has stated that treatment has been well-tolerated by patients and easily administered by hospital staff on standard dialysis equipment we are hopeful to get some insight at the upcoming 2009 International Sepsis Symposium to be held in Amsterdam, November 11-14. Anxious investors hungrily await.
The technology is on the cutting edge, it has a low cost to manufacture, a long shelf life, is easy to use, and is very compatible with standard dialysis equipment. Unlike a drug, which can have many adverse side effects, this device is very low risk, which will benefit the company greatly during the CE mark and FDA approval process. Medical devices have a very high rate of approval and with shorter timelines, especially ones with a need as great as this.
Research explores the health benefits of resistant starch in plant-based diets